Zollinger‑Ellison Disease (Type II Gastrinoma) – A Patient‑Focused Medical Guide
Overview
Zollinger‑Ellison disease (ZED) is a rare, hormonal disorder caused by a gastrin‑producing tumor (gastrinoma) that most often originates in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to produce massive amounts of gastric acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption.
Type II gastrinoma refers specifically to sporadic (non‑MEN1) gastrinomas, which account for roughly 25–30 % of all ZED cases. The remaining 70–75 % are associated with multiple endocrine neoplasia type 1 (MEN‑1) and are sometimes called “type I” gastrinomas.
- Who it affects: Adults age 30–60, slightly more common in men (M:F ≈ 1.3:1).
- Prevalence: Approximately 1 in 100,000–1 in 1,000,000 people worldwide (Mayo Clinic; NIH).
- Geography: No strong ethnic or geographic predilection, though most reported cases come from North America and Europe, likely reflecting diagnostic capacity.
Symptoms
Because excessive gastric acid affects the entire gastrointestinal (GI) tract, ZED produces a broad symptom profile. Symptoms may be intermittent early on and become more constant as the tumor grows.
Gastro‑intestinal symptoms
- Recurrent peptic ulcers: Often multiple, atypical locations (duodenum, jejunum, colon), and resistant to standard ulcer therapy.
- Epigastric or upper‑abdominal pain: Burning or gnawing pain that may improve with meals or antacids.
- Diarrhea: Frequent, watery stools; can be due to acid‑induced secretory diarrhea or bile‑acid malabsorption.
- Steatorrhea (fatty stools): Malabsorption of fat from acid‑mediated inactivation of pancreatic enzymes.
- Nausea & vomiting: May accompany ulcer pain or be secondary to gastric outlet obstruction.
- Gastrointestinal bleeding: Melena or hematemesis from ulcer erosion.
Systemic & nutritional symptoms
- Weight loss: From malabsorption, chronic diarrhea, and decreased appetite.
- Fatigue & anemia: Chronic blood loss or iron deficiency.
- Electrolyte disturbances: Low potassium or magnesium due to chronic diarrhea.
Symptoms related to tumor spread (metastasis)
- Abdominal mass or fullness.
- Back pain (pancreatic involvement).
- Jaundice (if tumor compresses the bile duct).
Causes and Risk Factors
ZED is fundamentally a neuro‑endocrine tumor of the gastrin‑producing G‑cells. The exact trigger for sporadic (type II) gastrinomas is unknown, but several factors are recognized.
Genetic factors
- MEN‑1 syndrome: Inherited mutation of the MEN1 tumor suppressor gene. While this defines type I gastrinomas, families with MEN‑1 have a markedly higher risk of any gastrinoma.
- Somatic mutations: KRAS, TP53, and other oncogenic alterations have been identified in sporadic gastrinomas, suggesting a multistep carcinogenic process.
Environmental & lifestyle factors
- Smoking – associated with many neuro‑endocrine tumors.
- Chronic H. pylori infection – may increase gastric mucosal susceptibility but is not a direct cause.
Who is at higher risk?
- Adults aged 30–60, especially males.
- Individuals with a family history of MEN‑1 or other neuro‑endocrine tumors.
- People with longstanding H. pylori infection or chronic gastritis (though evidence is modest).
Diagnosis
Diagnosing ZED requires a combination of clinical suspicion, biochemical testing, and imaging to locate the tumor.
Biochemical confirmation
- Fasting serum gastrin level: A level >1000 pg/mL (normal <100 pg/mL) is strongly suggestive. Levels >10‑fold the upper limit of normal, especially with a gastric pH <2, are diagnostic (NIH).
- Secretin stimulation test: In patients with borderline gastrin levels, an intravenous bolus of secretin paradoxically raises gastrin >120 pg/mL in ZED.
- Gastric pH measurement: Low gastric acidity (pH < 2) supports the diagnosis.
Imaging studies
- Multiphasic contrast CT scan (pancreas protocol): Detects tumors >1 cm and assesses liver metastases.
- Magnetic Resonance Imaging (MRI): Particularly useful for liver lesions.
- Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: High sensitivity for neuro‑endocrine tumors, including small duodenal gastrinomas.
- Endoscopic ultrasound (EUS): Allows fine‑needle aspiration of pancreatic/duodenal lesions.
Histopathology (if tissue obtained)
Biopsy reveals well‑differentiated neuro‑endocrine cells staining positive for gastrin and chromogranin A. Ki‑67 index helps grade tumor aggressiveness.
Treatment Options
Management aims to control acid hypersecretion, eradicate or reduce tumor burden, and monitor for recurrence.
Medical therapy – acid control
- High‑dose proton pump inhibitors (PPIs): Omeprazole 60‑120 mg/day or equivalent; often required for life. PPIs are the cornerstone and normalize gastric pH in >90 % of patients (Cleveland Clinic).
- H2‑receptor antagonists: Used as adjuncts if PPIs alone are insufficient.
- Potassium‑competitive acid blockers (e.g., vonoprazan): Emerging option for refractory cases.
Surgical treatment
- Localized disease: En‑bloc resection of the primary gastrinoma (duodenotomy with excision or pancreaticoduodenectomy) offers the best chance of cure.
- Metastatic disease: Cytoreductive surgery (debulking) plus liver metastasis resection when feasible.
- Laparoscopic approaches: Increasingly used for small duodenal lesions.
Targeted and systemic therapies
- Somatostatin analogues (Octreotide, Lanreotide): Inhibit gastrin release and can stabilize tumor growth.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE: For progressive, somatostatin‑receptor positive disease; improves progression‑free survival.
- Chemotherapy: Typically reserved for high‑grade neuro‑endocrine carcinoma; regimens may include streptozocin, 5‑FU, or temozolomide.
Other interventions
- Radiofrequency ablation (RFA) or microwave ablation: For isolated liver metastases.
- Liver transplantation: Considered in highly selected patients with unresectable liver disease and controlled primary tumor.
Living with Zollinger‑Ellison Disease (type II Gastrinoma)
Long‑term management blends medication adherence, monitoring, and lifestyle adjustments.
Medication adherence
- Take PPIs exactly as prescribed; never skip doses.
- Schedule regular follow‑up labs: gastrin level, liver function tests, and electrolyte panels every 6‑12 months.
Dietary tips
- Prefer low‑fat, low‑acid foods (e.g., boiled grains, steamed vegetables, lean protein).
- Avoid trigger foods that provoke ulcer pain: spicy foods, caffeine, alcohol, citrus, and carbonated drinks.
- Small, frequent meals reduce gastric acid spikes.
- Stay hydrated; oral rehydration solutions help replace electrolytes lost in diarrhea.
Monitoring & follow‑up
- Annual imaging (CT or MRI) to detect recurrence or new metastases.
- Endoscopic surveillance every 2–3 years for ulcer healing and early detection of new lesions.
- Genetic counseling if MEN‑1 is suspected.
Psychosocial support
- Join patient support groups (e.g., NET Patient Foundation).
- Consider counseling to address anxiety related to chronic disease.
Prevention
Because ZED arises from sporadic genetic mutations, primary prevention is limited. However, risk reduction strategies are advisable.
- Smoking cessation: Reduces neuro‑endocrine tumor risk.
- Treat H. pylori infection: Eradication may lower ulcer burden, though it doesn’t prevent gastrinoma.
- Regular medical check‑ups: Early evaluation of unexplained ulcer disease can lead to earlier diagnosis.
- Family screening: In families with MEN‑1, genetic testing and periodic imaging are recommended.
Complications
If left untreated or inadequately controlled, ZED can lead to serious health issues.
- Perforated peptic ulcer: Acute abdominal emergency with risk of sepsis.
- Upper‑GI bleeding: May require endoscopic or surgical intervention.
- Malabsorption & nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficits, osteopenia, and anemia.
- Metastatic disease: Liver is the most common site; can cause hepatic failure.
- Gastro‑enteric strictures: From chronic ulcer scarring, leading to obstruction.
- Refractory diarrhea: Can cause severe dehydration and electrolyte imbalance.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with your usual medication.
- Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools (melena).
- Signs of dehydration: dizziness, fainting, rapid heart rate, dry mouth, or reduced urine output.
- Severe, persistent diarrhea leading to weakness or confusion.
- Sudden swelling or pain in the right upper abdomen suggesting liver metastasis complications.
- High fever, chills, or worsening abdominal distension (possible perforation or infection).
Prompt treatment can be life‑saving.
References
- Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/diagnosis-treatment (accessed May 2026).
- National Institutes of Health (NIH). Guidelines for the Diagnosis and Management of Gastrinomas, 2022.
- Cleveland Clinic. Zollinger‑Ellison Syndrome: Overview and Treatment. https://my.clevelandclinic.org/health/diseases/15130-zollinger-ellison-syndrome (accessed May 2026).
- World Health Organization. Neuroendocrine Tumors: Classification and Management, 2021.
- American Cancer Society. Neuroendocrine Tumors of the Pancreas, 2023.
- Falch C, Bernier M, Abraham SC. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” Gastroenterology Clinics. 2022;51(2):321‑336.